Revolution Medicines Inc (NASDAQ:RVMD) has a beta value of 1.10 and has seen 1.02 million shares traded in the recent trading session. The company, currently valued at $7.25B, closed the recent trade at $38.94 per share which meant it lost -$1.1 on the day or -2.76%% during that session. The RVMD stock price is -60.25% off its 52-week high price of $62.40 and 25.09% above the 52-week low of $29.17. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.63 million shares traded. The 3-month trading volume is 1.91 million shares.
The consensus among analysts is that Revolution Medicines Inc (RVMD) is Buy stock at the moment, with a recommendation rating of 1.08. 1 analysts rate the stock as a Sell, while 1 rate it as Overweight. 0 out of 13 have rated it as a Hold, with 11 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.12.
Revolution Medicines Inc (NASDAQ:RVMD) trade information
Sporting -2.76%% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the RVMD stock price touched $38.94 or saw a rise of 4.21%. Year-to-date, Revolution Medicines Inc shares have moved 3.72%, while the 5-day performance has seen it change -2.10%. Over the past 30 days, the shares of Revolution Medicines Inc (NASDAQ:RVMD) have changed 0.35%. Short interest in the company has seen 18.36 million shares shorted with days to cover at 9.09.
Wall Street analysts have a consensus price target for the stock at $71, which means that the shares’ value could jump 45.15% from the levels at last check today.. The projected low price target is $64.0 while the price target rests at a high of $72.0. In that case, then, we find that the latest price level in today’s session is -84.9% off the targeted high while a plunge would see the stock gain -64.36% from the levels at last check today..
Revolution Medicines Inc (RVMD) estimates and forecasts
The company’s shares have lost -9.39% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
9 analysts offering their estimates for the company have set an average revenue estimate of 500k for the current quarter. 9 have an estimated revenue figure of 500k for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -27.80% over the past 5 years. Earnings growth for 2025 is a modest -32.12% while over the next 5 years, the company’s earnings are expected to decrease by -6.42%.
RVMD Dividends
Revolution Medicines Inc is expected to release its next earnings report on 2025-May-07 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Revolution Medicines Inc (NASDAQ:RVMD)’s Major holders
Insiders own 1.99% of the company shares, while shares held by institutions stand at 105.95% with a share float percentage of 108.11%. Investors are also buoyed by the number of investors in a company, with Revolution Medicines Inc having a total of 399.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 14.38 million shares worth more than $558.02 million. As of 2024-06-30, VANGUARD GROUP INC held 8.7066% of shares outstanding.
The other major institutional holder is WELLINGTON MANAGEMENT GROUP LLP, with the holding of over 13.66 million shares as of 2024-06-30. The firm’s total holdings are worth over $530.15 million and represent 8.2718% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund . As of Mar 31, 2025 , the former fund manager holds about 2.85% shares in the company for having 5.31 shares of worth $207.14 million while later fund manager owns 4.3 shares of worth $167.6 million as of Jan 31, 2025 , which makes it owner of about 2.31% of company’s outstanding stock.
